Carbenicillina may be available in the countries listed below.
Carbenicillina (DCIT) is known as Carbenicillin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Sotalol NM Pharma may be available in the countries listed below.
Sotalol hydrochloride (a derivative of Sotalol) is reported as an ingredient of Sotalol NM Pharma in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion and cough due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Respi-Tann Chewable Tablets are a decongestant and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Respi-Tann Chewable Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Respi-Tann Chewable Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Respi-Tann Chewable Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Respi-Tann Chewable Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Respi-Tann Chewable Tablets.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Respi-Tann side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Respi-Tann Chewable Tablets at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Respi-Tann Chewable Tablets out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Respi-Tann Chewable Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Vancomicina Combino Pharm may be available in the countries listed below.
Vancomycin is reported as an ingredient of Vancomicina Combino Pharm in the following countries:
Vancomycin hydrochloride (a derivative of Vancomycin) is reported as an ingredient of Vancomicina Combino Pharm in the following countries:
International Drug Name Search
CTC Spray may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlortetracycline hydrochloride (a derivative of Chlortetracycline) is reported as an ingredient of CTC Spray in the following countries:
International Drug Name Search
Cromogen Easi-Breath may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cromogen Easi-Breath in the following countries:
International Drug Name Search
Class: Immunosuppressive Agents
VA Class: IM600
CAS Number: 179045-86-4
Brands: Simulect
Should be prescribed only by clinicians experienced in immunosuppressive therapy and the management of organ transplant patients.1
The clinician responsible for the administration of basiliximab should have complete information necessary for follow-up of the patient.1
Should only be administered by medical personnel trained in administration of the drug and who have adequate laboratory and supportive medical resources.1
Immunosuppressive agent; recombinant DNA-derived chimeric (human-murine) monoclonal antibody.1 2 3 4 5
Prevention of renal allograft rejection.1 2 3 5
Manufacturer recommends use in conjunction with cyclosporine and corticosteroids.1
Efficacy in preventing acute rejection of a second renal allograft or other solid organ transplants (e.g., liver transplantation) has not been demonstrated.1
Administer only by direct IV (“bolus”) injection or IV infusion via a central or peripheral line.1 7
Direct IV injection may be associated with nausea, vomiting, and local reactions, including pain.1 7
Administer in conjunction with cyclosporine and corticosteroid therapy.1
Administer only when it has been determined that the patient will receive the graft and concomitant immunosuppressive therapy.1
10 mg vial: add 2.5 mL of sterile water for injection.a Reconstituted solution is isotonic; may administer by direct IV injection or dilute for IV infusion.a
20 mg vial: add 5 mL of sterile water for injection.1 Reconstituted solution is isotonic; may administer by direct IV injection or dilute for IV infusion.1
Shake vial gently to dissolve.1
10 mg vial: for IV infusion, dilute reconstituted solution to 25 mL with 0.9% sodium chloride or 5% dextrose injection.a
20 mg vial: for IV infusion, dilute reconstituted solution to 50 mL with 0.9% sodium chloride or 5% dextrose injection.1
Gently invert the IV bag to mix the solution without foaming; do not shake.1
For IV infusion, administer over 20–30 minutes.1
Weight < 35 kg: 2 doses, 10 mg each, by direct IV injection or IV infusions.1 7
Weight ≥ 35 kg: 2 doses, 20 mg each.1 7
Administer first dose within 2 hours prior to transplantation, second dose 4 days after transplantation.1 2 3 5
Withhold second dose if complications (e.g., severe hypersensitivity reactions, graft loss) occur after the first dose.1
2 doses, 20 mg each, by direct IV injection or IV infusion.
Administer first dose within 2 hours prior to transplantation, second dose 4 days after transplantation.1 2 3 5
Withhold second dose if complications (e.g., severe hypersensitivity reactions, graft loss) occur after the first dose.1
Not determined; at least one pediatric renal transplant patient received single 20-mg dose (2.3 mg/kg) without adverse events.1
Not determined; single doses up to 60 mg or divided doses over 3-5 days of up to 120 mg given without serious adverse effects.1
Dosage adjustment is not required for geriatric patients; in general, use immunosupressive agents with caution.1
Known hypersensitivity to basiliximab or any ingredient in the formulation.1
(See Boxed Warning.)
Monitor patients for lymphoproliferative disorders and/or opportunistic infections; risk is increased with immunosuppressive therapy.1
Neither complication occurred more often with basiliximab than with placebo in clinical trials.1
Severe, acute (onset within 24 hours) hypersensitivity reactions, including anaphylaxis, have occurred after initial basiliximab exposure and subsequent reexposure.1
Drugs to treat severe hypersensitivity reactions, including anaphylaxis, should be immediately available.1
In patients who have previously received the drug, a subsequent course of therapy with basiliximab should be given with extreme caution; risks of subsequent administration not known.1
If hypersensitivity reaction occurs, immediately and permanently discontinue basiliximab and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).1
Patients who have a severe hypersensitivity reaction to basiliximab should not receive the drug again.1
Not known whether the immune response to vaccines, infection, and other antigens is impaired during therapy or will remain impaired following therapy.1
An anti-idiotype antibody response has been detected in renal-transplant patients treated with basiliximab.1 5 No deleterious clinical effect and no evidence of faster basiliximab clearance or shorter duration of basiliximab saturation of IL-2Rα detected in the presence of anti-idiotype antibody.1 Clinical data suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded.1
Category B.1
Manufacturer recommends use of effective contraception before, during, and for 4 months following basiliximab use in women of childbearing potential.1
Not known whether basiliximab is distributed into milk.1 Discontinue nursing or the drug.1
Use in children 1–16 years of age for prevention of renal allograft rejection is supported by limited data from a pediatric safety and pharmacokinetic study.1 7
Limited data in patients ≥65 years of age suggest an adverse effect profile similar to that in younger adults; use immunosuppressive drugs with caution in such patients.1 7
Constipation, nausea, diarrhea, abdominal pain, vomiting, dyspepsia, hyperkalemia, hypokalemia, hyperglycemia, hyperuricemia, hypophosphatemia, hypercholesterolemia, headache, tremor, urinary tract infection, pain, peripheral edema, fever, viral infection, hypertension, dyspnea, upper respiratory tract infection, surgical wound complications, acne, insomnia, anemia.1 2 3
Drug | Interaction | Comments |
|---|---|---|
Immunosuppressive triple-agent regimen (azathioprine or mycophenolate mofetil with cyclosporine and corticosteroids) | Clearance of basiliximab reduced by 22% with azathioprine or by 51% with mycophenolate mofetil triple regimen; however, clearance consistent with dual regimens1 | Basiliximab dosage adjustment unnecessary1 |
Antilymphocyte globulin | No increase in adverse effects1 | |
Antithymocyte globulin | No increase in adverse effects1 | |
Azathioprine | No increase in adverse effects1 | |
Corticosteroids | No increase in adverse effects1 | |
Cyclosporine | No increase in adverse effects1 | |
Mycophenolate mofetil | No increase in adverse effects1 | |
Muromonab-CD3 | No increase in adverse effects1 |
Duration of clinically important IL-2 receptor blockade by basiliximab is unknown.a
Duration of basiliximab IL-2 Rα saturation when added to double regimen (cyclosporine and corticosteroids) averages 36 days in children and adults.a
Duration of basiliximab IL-2 Rα saturation varies with regimen; when added to triple regimens (cyclosporine and corticosteroids plus azathioprine or mycophenolate mofetil), duration averages 50 days with azathioprine regimen and 59 days with mycophenolate mofetil regimen.a
Generally, immune globulin molecules cross the placenta; not known whether basiliximab crosses placenta or is distributed into milk.a
Adults: average 7.2 days.a
Children 1–11 years of age: average 9.5 days.a
Children 12–16 years of age: average 9.1 days.a
In adults (20–69 years of age), half-life not affected by age.a
2–8°C.1
Use immediately or within 4 hours of preparation if stored at 15–30°C.1 7
Alternatively, may be stored at 2–8°C for up to 24 hours after preparation.1 7
Discard unused solutions within 24 hours.1
Manufacturer makes no storage recommendation.a
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
|---|
5% Dextrose Injection |
0.9% Sodium Chloride Injection |
Incompatibility not observed with polyvinyl chloride bags or infusion sets.1
Unknown whether basiliximab is compatible with other IV drugs.1
Do not mix with other drugs or infuse simultaneously with other drugs in the same IV line.1
A recombinant DNA-derived chimeric (human-murine) monoclonal antibody immunosuppressive agent.1 2 3 4 5
Competitively inhibits IL-2-mediated lymphocyte activation, integral to the cell-mediated immune response involved in allograft rejection.1 2
Binds with high affinity to IL-2Rα and inhibits binding of IL-2 to antigenically stimulated T lymphocytes.1 2
Importance of understanding potential benefits of basiliximab and risks of immunosuppressive therapy.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | Injection | 10 mg | Simulect | Novartis |
20 mg | Simulect | Novartis |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2004. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Novartis Pharmaceuticals Corporation. Simulect (basiliximab) for injection prescribing information. East Hanover, NJ; 2000 Jun.
2. Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997; 350:1193-8. [IDIS 394766] [PubMed 9652559]
3. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation. 1999; 67:276-84. [IDIS 422843] [PubMed 10075594]
4. Kovarik JM, Kahan BD, Rajagopalan PR et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation. 1999; 68:1288-94. [IDIS 439006] [PubMed 10573065]
5. Onrust SV, Wiseman LR. Basiliximab. Drugs. 1999; 57:207-13. [PubMed 10188761]
6. Ponticelli C, Yussim A, Cambi V et al. Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine. Transplant Proc. 2001; 33:1009-10. [IDIS 461658] [PubMed 11267167]
7. Novartis Pharmaceuticals Corporation: Personal communication.
a. Novartis. Simulect (basiliximab) prescribing information. East Hanover, NJ; 2003 Jan.
Ceferro may be available in the countries listed below.
Ferrous Sulfate is reported as an ingredient of Ceferro in the following countries:
International Drug Name Search
Lucrin may be available in the countries listed below.
Leuprorelin acetate (a derivative of Leuprorelin) is reported as an ingredient of Lucrin in the following countries:
International Drug Name Search
Tylatrat may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tylosin tartrate (a derivative of Tylosin) is reported as an ingredient of Tylatrat in the following countries:
International Drug Name Search
Doloflam may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Doloflam in the following countries:
International Drug Name Search
